Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Constellation Pharmaceuticals Congratulates Dr. David Allis and Dr. Michael Grunstein, Winners of the 2018 Lasker Award


Posted on: 12 Sep 18

CAMBRIDGE, Mass., Sept. 12, 2018 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST) today congratulated Dr. C. David Allis and Dr. Michael Grunstein, the co-recipients of the 2018 Albert Lasker Basic Medical Research Award.  These two eminent scientists were honored for their pioneering work in epigenetics, the field that studies how chemical modifications of histones, the protein component of chromatin around which DNA is wound, impact gene expression. 

The Lasker Award is one of the most prestigious awards in medicine.  In a statement, the Lasker Foundation cited how the work of Drs. Allis and Grunstein “unveiled a previously hidden layer of gene control and broke open a new field.”

Dr. Allis is the Joy and Jack Fishman Professor and Head of the Laboratory of Chromatin Biology and Epigenetics at The Rockefeller University.  He co-founded Constellation Pharmaceuticals in 2008 with Drs. Danny Reinberg and Yang Shi.  Dr. Grunstein is Professor Emeritus in the Department of Biological Chemistry at the David Geffen School of Medicine at UCLA.

About Constellation Pharmaceuticals

Constellation Pharmaceuticals is a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics that address serious unmet medical needs in patients with cancers associated with abnormal gene expression or drug resistance.  With a decade of experience in the field, the Company has a deep understanding of how epigenetic regulators modulate gene expression in cancer cells and in the tumor and immune microenvironment.  Constellation is translating these insights to advance the Company’s two lead clinical programs, the EZH2 inhibitor CPI-1205 for metastatic castration-resistant prostate cancer and solid tumors and the BET inhibitor CPI-0610 for myelofibrosis, and to explore other novel targets for which cancer epigenetics may enhance outcomes over currently available treatment options.

Contact

Ronald Aldridge
Investor Relations
Constellation Pharmaceuticals
+1 617-714-0539
ron.aldridge@constellationpharma.com

Lauren Arnold
Media Relations
MacDougall Biomedical Communications
+1 781-235-3060
larnold@macbiocom.com

GlobeNewswire
globenewswire.com

Last updated on: 13/09/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.